Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo

Michael Y. Bonner, Isabella Karlsson, Monica Rodolfo, Rebecca S. Arnold, Elisabetta Vergani, Jack L. Arbiser

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The majority of human melanomas bears BRAF mutations and thus is treated with inhibitors of BRAF, such as vemurafenib. While patients with BRAF mutations often demonstrate an initial dramatic response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the treatment of these aggressive melanomas. Honokiol is a small molecule compound derived from Magnolia grandiflora that has activity against solid tumors and hematopoietic neoplasms. In order to increase the lipophilicity of honokiol, we have synthesized honokiol DCA, the dichloroacetate ester of honokiol. In addition, we synthesized a novel fluorinated honokiol analog, bis-trifluoromethyl-bis-(4-hydroxy-3-allylphenyl) methane (hexafluoro). Both compounds exhibited activity against A375 melanoma in vivo, but honokiol DCA was more active. Gene arrays comparing treated with vehicle control tumors demonstrated induction of the respiratory enzyme succinate dehydrogenase B (SDHB) by treatment, suggesting that our honokiol analogs induce respiration in vivo. We then examined its effect against a pair of melanomas, LM36 and LM36R, in which LM36R differs from LM36 in that LM36R has acquired vemurafenib resistance. Honokiol DCA demonstrated in vivo activity against LM36R (vemurafenib resistant) but not against parental LM36. Honokiol DCA and hexafluoro inhibited the phosphorylation of DRP1, thus stimulating a phenotype suggestive of respiration through mitochondrial normalization. Honokiol DCA may act in vemurafenib resistant melanomas to increase both respiration and reactive oxygen generation, leading to activity against aggressive melanoma in vivo.

Original languageEnglish
Pages (from-to)12857-12868
Number of pages12
JournalOncotarget
Volume7
Issue number11
DOIs
Publication statusPublished - Mar 15 2016

Fingerprint

Melanoma
Respiration
Magnolia
PLX4032
honokiol
Mutation
Enzyme Induction
Succinate Dehydrogenase
Methane
Hematologic Neoplasms
Neoplasms
Esters
Phosphorylation
Oxygen
Phenotype
Recurrence
Therapeutics
Genes

Keywords

  • Melanoma
  • Mitochondria
  • Reactive oxygen
  • Vemurafenib-resistant
  • Xenographs

ASJC Scopus subject areas

  • Oncology

Cite this

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. / Bonner, Michael Y.; Karlsson, Isabella; Rodolfo, Monica; Arnold, Rebecca S.; Vergani, Elisabetta; Arbiser, Jack L.

In: Oncotarget, Vol. 7, No. 11, 15.03.2016, p. 12857-12868.

Research output: Contribution to journalArticle

Bonner, Michael Y. ; Karlsson, Isabella ; Rodolfo, Monica ; Arnold, Rebecca S. ; Vergani, Elisabetta ; Arbiser, Jack L. / Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. In: Oncotarget. 2016 ; Vol. 7, No. 11. pp. 12857-12868.
@article{5c826d0ce70a4b78bd1bbe9c6c09d5cb,
title = "Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo",
abstract = "The majority of human melanomas bears BRAF mutations and thus is treated with inhibitors of BRAF, such as vemurafenib. While patients with BRAF mutations often demonstrate an initial dramatic response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the treatment of these aggressive melanomas. Honokiol is a small molecule compound derived from Magnolia grandiflora that has activity against solid tumors and hematopoietic neoplasms. In order to increase the lipophilicity of honokiol, we have synthesized honokiol DCA, the dichloroacetate ester of honokiol. In addition, we synthesized a novel fluorinated honokiol analog, bis-trifluoromethyl-bis-(4-hydroxy-3-allylphenyl) methane (hexafluoro). Both compounds exhibited activity against A375 melanoma in vivo, but honokiol DCA was more active. Gene arrays comparing treated with vehicle control tumors demonstrated induction of the respiratory enzyme succinate dehydrogenase B (SDHB) by treatment, suggesting that our honokiol analogs induce respiration in vivo. We then examined its effect against a pair of melanomas, LM36 and LM36R, in which LM36R differs from LM36 in that LM36R has acquired vemurafenib resistance. Honokiol DCA demonstrated in vivo activity against LM36R (vemurafenib resistant) but not against parental LM36. Honokiol DCA and hexafluoro inhibited the phosphorylation of DRP1, thus stimulating a phenotype suggestive of respiration through mitochondrial normalization. Honokiol DCA may act in vemurafenib resistant melanomas to increase both respiration and reactive oxygen generation, leading to activity against aggressive melanoma in vivo.",
keywords = "Melanoma, Mitochondria, Reactive oxygen, Vemurafenib-resistant, Xenographs",
author = "Bonner, {Michael Y.} and Isabella Karlsson and Monica Rodolfo and Arnold, {Rebecca S.} and Elisabetta Vergani and Arbiser, {Jack L.}",
year = "2016",
month = "3",
day = "15",
doi = "10.18632/oncotarget.7289",
language = "English",
volume = "7",
pages = "12857--12868",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "11",

}

TY - JOUR

T1 - Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo

AU - Bonner, Michael Y.

AU - Karlsson, Isabella

AU - Rodolfo, Monica

AU - Arnold, Rebecca S.

AU - Vergani, Elisabetta

AU - Arbiser, Jack L.

PY - 2016/3/15

Y1 - 2016/3/15

N2 - The majority of human melanomas bears BRAF mutations and thus is treated with inhibitors of BRAF, such as vemurafenib. While patients with BRAF mutations often demonstrate an initial dramatic response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the treatment of these aggressive melanomas. Honokiol is a small molecule compound derived from Magnolia grandiflora that has activity against solid tumors and hematopoietic neoplasms. In order to increase the lipophilicity of honokiol, we have synthesized honokiol DCA, the dichloroacetate ester of honokiol. In addition, we synthesized a novel fluorinated honokiol analog, bis-trifluoromethyl-bis-(4-hydroxy-3-allylphenyl) methane (hexafluoro). Both compounds exhibited activity against A375 melanoma in vivo, but honokiol DCA was more active. Gene arrays comparing treated with vehicle control tumors demonstrated induction of the respiratory enzyme succinate dehydrogenase B (SDHB) by treatment, suggesting that our honokiol analogs induce respiration in vivo. We then examined its effect against a pair of melanomas, LM36 and LM36R, in which LM36R differs from LM36 in that LM36R has acquired vemurafenib resistance. Honokiol DCA demonstrated in vivo activity against LM36R (vemurafenib resistant) but not against parental LM36. Honokiol DCA and hexafluoro inhibited the phosphorylation of DRP1, thus stimulating a phenotype suggestive of respiration through mitochondrial normalization. Honokiol DCA may act in vemurafenib resistant melanomas to increase both respiration and reactive oxygen generation, leading to activity against aggressive melanoma in vivo.

AB - The majority of human melanomas bears BRAF mutations and thus is treated with inhibitors of BRAF, such as vemurafenib. While patients with BRAF mutations often demonstrate an initial dramatic response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the treatment of these aggressive melanomas. Honokiol is a small molecule compound derived from Magnolia grandiflora that has activity against solid tumors and hematopoietic neoplasms. In order to increase the lipophilicity of honokiol, we have synthesized honokiol DCA, the dichloroacetate ester of honokiol. In addition, we synthesized a novel fluorinated honokiol analog, bis-trifluoromethyl-bis-(4-hydroxy-3-allylphenyl) methane (hexafluoro). Both compounds exhibited activity against A375 melanoma in vivo, but honokiol DCA was more active. Gene arrays comparing treated with vehicle control tumors demonstrated induction of the respiratory enzyme succinate dehydrogenase B (SDHB) by treatment, suggesting that our honokiol analogs induce respiration in vivo. We then examined its effect against a pair of melanomas, LM36 and LM36R, in which LM36R differs from LM36 in that LM36R has acquired vemurafenib resistance. Honokiol DCA demonstrated in vivo activity against LM36R (vemurafenib resistant) but not against parental LM36. Honokiol DCA and hexafluoro inhibited the phosphorylation of DRP1, thus stimulating a phenotype suggestive of respiration through mitochondrial normalization. Honokiol DCA may act in vemurafenib resistant melanomas to increase both respiration and reactive oxygen generation, leading to activity against aggressive melanoma in vivo.

KW - Melanoma

KW - Mitochondria

KW - Reactive oxygen

KW - Vemurafenib-resistant

KW - Xenographs

UR - http://www.scopus.com/inward/record.url?scp=84962798369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962798369&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7289

DO - 10.18632/oncotarget.7289

M3 - Article

AN - SCOPUS:84962798369

VL - 7

SP - 12857

EP - 12868

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -